Absolutely.
That is how micro stocks explode on the scene with momentum to sustain. I can see the EU patent as critical as it would force their past partners in Thai and Australia to pay for using their procedure. Also probably needed to solidify a relationship with the likes of Chaum/others. That process is so unrefined I don't know if patent decision is a week away or a year yet..
From what I gather, the minimally manip may be a hard sell with FDA. But I could see an abridged IND path which benefits cost and time of IND. All these INDs discussed in PRs the past 18 months AND with very prominent people are waiting on something. This is where Andrews and the FDA come in. Probably also the streamlined reactor.
I think several other pieces could be in place. The hold up must center around whatever Andrews is doing with FDA.. Whether trying for minimally manip or building a reactor to increase cell viability or what.
Or maybe Andrews group is out and not doing anything... Which would also explain the silence.
They still state this dream goal of having Intellicell labs in many locations, which only would make sense if minimally manipulated is seriously on the table.
In any case, I suspect we will have to wait until the 10-k before a behind the scenes glimpse of OUR publicly traded company. Not a way I would treat shareholders....
News 
Market Data 
Discover 
AI
